弥漫大B细胞淋巴瘤的分子靶向治疗  

Molecular targeted therapy of diffuse large B cell lymphoma

作　　者：杨国荣[1] 钟美佐[1] 

机构地区：[1]中南大学湘雅医院肿瘤科,长沙410008

出　　处：《国际肿瘤学杂志》2012年第4期311-315,共5页Journal of International Oncology

摘　　要：弥漫大B细胞淋巴瘤（DLBCL）是最常见的成人非霍奇金淋巴瘤。现阶段利妥昔单抗与CHOP方案（环磷酰胺＋多柔比星＋长春新碱＋泼尼松）的联合应用已显著改善了DLBCL的预后，约50％的DLBCL可以治愈。但由于肿瘤的异质性，对于难治、复发的DLBCL仍然缺乏行之有效的治疗方法。随着基因表达谱的运用及对淋巴瘤细胞内活化信号途径的深入研究，发现了很多潜在的治疗靶点。The diffuse large B cell lymphoma （DLBCL） is the most common aduh non-hodgkin lymphoma. At present, rituximab in combination with CHOP program has significantly improved the prognosis of DLBCL, and about 50% of the DLBCL can be cured. However, due to the heterogeneity of the tumor, the refractory and relapsed DLBCL is still lack of effective treatment methods. With the application of gene expression profile （GEP） and the thorough research of the activation of lymphoma cells signal way, a lot of potential therapeutic targets have been found.

关 键 词：淋巴瘤 大B细胞 弥漫性 分子靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]